JOHN VIERLING to Aged, 80 and over
This is a "connection" page, showing publications JOHN VIERLING has written about Aged, 80 and over.
Connection Strength
0.103
-
Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A population-based risk factor assessment using vibration controlled transient elastography (VCTE). PLoS One. 2021; 16(11):e0260320.
Score: 0.020
-
Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials. Am J Gastroenterol. 2018 06; 113(6):863-871.
Score: 0.016
-
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018 01 25; 378(4):354-369.
Score: 0.016
-
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017 06 01; 376(22):2134-2146.
Score: 0.015
-
Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016 May; 63(5):1493-505.
Score: 0.014
-
Prospective Multicenter Observational Study of Overt Hepatic Encephalopathy. Dig Dis Sci. 2016 06; 61(6):1728-34.
Score: 0.014
-
6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology. 2003 Aug; 125(2):298-303.
Score: 0.006
-
Transjugular intrahepatic portosystemic shunt: efficacy for the treatment of portal hypertension and impact on liver transplantation. Am Surg. 1996 Oct; 62(10):835-9.
Score: 0.004